At the news
? NEUTRALIMPACT 3/10 8-K filed Apr 30, 2026 at 08:12 ET
Halozyme appointed Darren Snellgrove as permanent CFO, effective June 8, 2026, replacing interim CFO David Ramsay who will stay on in an advisory role. Snellgrove brings deep biopharma finance experience from 27 years at Johnson & Johnson, most recently as VP of Investor Relations and previously as CFO of J&J's Pharmaceutical sector. This is a routine executive appointment with no material financial impact.
- Darren Snellgrove appointed CFO effective June 8, 2026, replacing interim CFO David Ramsay
- Snellgrove spent 27 years at Johnson & Johnson, most recently as VP of Investor Relations and previously as CFO of J&J's Pharmaceutical sector
- Annual base salary of $670,000 with 50% bonus target, new-hire equity awards totaling $7,200,000 ($3.2M RSUs + $4.0M stock options), and a $350,000 sign-on cash bonus
- Current interim CFO David Ramsay will remain in an advisory role during the transition
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access